Jubilant HollisterStier Sterile Expansion Project Underway

Jubilant HollisterStier Sterile Expansion Project Underway

Montreal, QC, Canada., August 14, 2013  Jubilant HollisterStier announced today that the Montreal-based manufacturing facility has completed the first phase of an expansion of their sterile manufacturing capacity, with the addition of a new ampoule filling line utilizing a rigid barrier system. This expansion of capacity is a continuation of improvements being made to further enhance the site's sterile manufacturing capabilities. 

The new manufacturing area will expand ampoule manufacturing capacity in Montreal  by nearly two hundred percent.  In addition, expansions to the sterile areas at Jubilant HollisterStier have been optimized through successful implementation of Lean and Six Sigma initiatives.

The new area is scheduled to be ready for product on September 9th 2013. A significant portion of the expanded capacity has already been allocated to new customer products that will be manufactured at the site.

"We are excited to complete this phase of our optimization strategy in sterile manufacturing.  Our site in Montreal will be well positioned to continue offering multiple dosage platforms for our global customers. We have been fortunate to secure several new contracts that will utilize our expanded capacity starting this year" said Jubilant HollisterStier Chief Executive Officer, Marcelo Morales.


About Jubilant HollisterStier

Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Jubilant HollisterStier provides its customers manufacturing services to aseptically fill liquid and lyophilized products and semi-solid dosage forms at its facility in Montreal, Quebec, Canada. For more info about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of almost 6400 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 90 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.